FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Pharmacy-based PrEP Delivery in Kenya

Not Applicable

Recruiting

Conditions: Hiv

Interventions: Behavioral: Pharmacy PrEP/PEP for a fee
Behavioral: Pharmacy PrEP/PEP for free
Behavioral: Pharmacy referral to clinic-based PrEP/PEP
Behavioral: HTS counselor supported pharmacy PrEP/PEP for free

First Posted Date: 2023-05-03

Last Posted Date: 2024-12-20

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 5944

Registration Number: NCT05842122

Locations: 🇰🇪
Kenya Medical Research Institute, Kisumu, Kenya
🇰🇪
Partners in Health & Research Development, Thika, Kenya

A Checklist (Advanced Care Planning) for The Assessment of Mobility Needs in Patients With Sarcoma

Not Applicable

Not yet recruiting

Conditions: Metastatic Sarcoma
Sarcoma

Interventions: Behavioral: Assessment
Other: Questionnaire Administration
Other: Interview
Other: Electronic Health Record Review

First Posted Date: 2023-04-28

Last Posted Date: 2024-12-09

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT05835154

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Clinical Decision Support Tools to Increase Human Papillomavirus (HPV) Vaccination in Adolescents in Pharmacies

Not Applicable

Terminated

Conditions: Human Papillomavirus-Related Carcinoma

Interventions: Other: Educational Activity
Other: Discussion
Other: Survey Administration
Behavioral: Healthcare Activity

First Posted Date: 2023-04-26

Last Posted Date: 2024-12-19

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 31

Registration Number: NCT05831540

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Phase I Open Label BCG Clinical Trial Assessing TB Drugs and Vaccines

Phase 1

Completed

Conditions: Tuberculosis

Interventions: Drug: BCG Vaccine USP
Drug: Isoniazid
Drug: Rifampin

First Posted Date: 2022-10-24

Last Posted Date: 2024-01-05

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT05592223

Locations: 🇺🇸
Fred Hutchinson Cancer Center, Seattle, Washington, United States

Design and Testing of a Web-Based Tool for the Improvement of End-of-Life Planning in Patients With Advanced Cancer

Not Applicable

Recruiting

Conditions: Hematopoietic and Lymphoid System Neoplasm
Locally Advanced Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm

Interventions: Other: Best Practice
Other: Internet-Based Intervention
Other: Questionnaire Administration

First Posted Date: 2022-10-03

Last Posted Date: 2024-11-21

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 100

Registration Number: NCT05564468

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Optimizing Screening for Cervical Cancer Among Women Living With HIV in the Dominican Republic

Not Applicable

Active, not recruiting

Conditions: Malignant Female Reproductive System Neoplasm

Interventions: Procedure: Biospecimen Collection
Other: Interview

First Posted Date: 2022-09-27

Last Posted Date: 2024-08-09

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 619

Registration Number: NCT05556772

Locations: 🇩🇴
Instituto Dermatológico Dominicano y Cirugía de Piel (IDCP) "Dr. Huberto Bogaert Diaz", Santo Domingo, Dominican Republic

A Video Intervention to Decrease Patient Fear of Colonoscopy After a Positive Fecal Immunochemical Test

Not Applicable

Completed

Conditions: Colorectal Carcinoma

Interventions: Other: Media Intervention
Other: Best Practice
Other: Questionnaire Administration

First Posted Date: 2022-07-14

Last Posted Date: 2024-05-30

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 66

Registration Number: NCT05458986

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Phase 1

Recruiting

Conditions: Refractory Diffuse Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Grade 3b Follicular Lymphoma
Refractory Grade 3b Follicular Lymphoma
Refractory Primary Mediastinal Large B-Cell Lymphoma
Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Recurrent Primary Mediastinal Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Lisocabtagene Maraleucel
Drug: Polymer-conjugated IL-15 Receptor Agonist NKTR-255
Procedure: X-Ray Imaging
Procedure: Echocardiography
Procedure: Multigated Acquisition Scan
Procedure: Bone Marrow Biopsy
Procedure: Bone Marrow Aspiration
Procedure: Lumbar Puncture
Procedure: Computed Tomography
Procedure: Positron Emission Tomography
Procedure: Biospecimen Collection
Procedure: Biopsy

First Posted Date: 2022-05-03

Last Posted Date: 2024-02-06

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 24

Registration Number: NCT05359211

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

A Tailored Screening and Smoking Cessation Program for the LGBTQ Community of Seattle

Not Applicable

Terminated

Conditions: Lung Carcinoma

Interventions: Behavioral: Patient Navigation
Other: Questionnaire Administration
Behavioral: Smoking Cessation Intervention
Procedure: Carbon Monoxide Measurement

First Posted Date: 2022-03-31

Last Posted Date: 2024-12-02

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 53

Registration Number: NCT05304390

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

A Multilevel Approach for Improvement in Screening of Colorectal Cancer in Rural Communities, The Screen to Save Trial

Not Applicable

Terminated

Conditions: Colorectal Carcinoma

Interventions: Other: Educational Intervention
Other: Fecal Immunochemical Test
Other: Questionnaire Administration

First Posted Date: 2022-03-23

Last Posted Date: 2022-12-15

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 8

Registration Number: NCT05291988

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Olympic Medical Cancer Care Center, Sequim, Washington, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy